Clinical Trials Logo

Clinical Trial Summary

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06240754
Study type Interventional
Source Washington University School of Medicine
Contact Kelly Bolton, M.D., Ph.D.
Phone 314-273-5711
Email bolton@wustl.edu
Status Not yet recruiting
Phase Phase 2
Start date June 30, 2024
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05102370 - A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance Phase 1
Recruiting NCT04102423 - CHIP/CCUS Natural History Protocol
Recruiting NCT03418038 - Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Phase 2
Recruiting NCT06063486 - Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms Phase 2
Recruiting NCT02958462 - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study N/A
Recruiting NCT05641831 - Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study Phase 2
Recruiting NCT05483010 - Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) Phase 2
Recruiting NCT04902833 - Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Recruiting NCT05030441 - Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 Phase 2